Project Information. a) Protocol. Rationale and aims of research:
|
|
- Jared Gilbert
- 7 years ago
- Views:
Transcription
1 Project Information a) Protocol Rationale and aims of research: Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system that afflicts roughly 1 in 1000 people in Northern regions of Europe and North America (Pryse- Phillips & Costello, 2001). MS patients frequently experience physical disability, severe fatigue, and depression. Cognitive deficits are also common. In fact, over 50% of MS patients experience problems with aspects of attention, processing speed, executive functioning, and learning (Rao et al., 1991). These cognitive symptoms are associated with problems managing independent activities of daily living, poorer vocational status, difficulty driving, and lower social functioning (Benedict et al., 2005; Higginson, Arnett, & Voss, 2000; Rao et al., 1991). As such, the identification of pharmacologic agents that improve cognition in MS may have wide ranging implications for patients overall quality of life. Aims: 1. Determine whether armodafinil ameliorates cognitive difficulties in MS as measured by objective neuropsychological tests. It is hypothesized that armodafinil will be associated with improved performance on tests of cognitive functioning. 2. Determine whether armodafinil ameliorates self-reported cognitive difficulties as measured by questionnaires. It is hypothesized that armodafinil will be associated with fewer selfreports of memory and other thinking problems. Results of similar or related studies: Armodafinil is a novel psychostimulant that has shown promise as a cognitive enhancer in normal adults and patient populations, including schizophrenia and attention deficit hyperactivity disorder (Baranski et al., 2004; Randall et al., 2005; Turner et al., 2004a; Turner et al., 2004b). Commonly prescribed to treat MS-related fatigue (Zifko, 2004), armodafinil is also an alertness-promoting agent that reduces lapses of attention and vigilance that are caused by sleep deprivation and fatiguing disorders (Baranski et al., 1998; Gill et al., 2005; Hirshkowitz et al., 2007). Indeed, it has been suggested that the nootropic effects of armodafinil may be magnified among people with pronounced fatigue and pre-existing cognitive difficulties (Muller et al., 2004; Randall et al., 2005). As MS patients frequently suffer from significant fatigue and neuropsychological deficits, armodafinil has strong potential as a highly efficacious cognitive enhancer in this population. Despite this, no published studies have examined the use of armodafinil to treat cognitive impairment in MS. The proposed study will examine how armodafinil impacts objective neuropsychological performance and self-reported cognitive difficulties in MS. Benefits and Risks: 1
2 Participants will receive a $150 economic benefit for participation. Aside from the monetary compensation, they will not receive any other direct benefits. The results of this study may help clinicians improve the treatment of cognitive dysfunction in MS. Armodafinil is used as the standard of care for MS-related fatigue. However, no studies have examined how armodafinil might impact cognition in MS. The most commonly observed adverse side effects of armodafinil include headache, stomach upset, dizziness, anxiety and insomnia. Armodafinil can also reduce the efficacy of steroidal contraceptives and has rarely been associated with heart palpitations and chest pain among people with a history of mitral valve prolapse (patients with a history of heart problems will be excluded). Very rarely, a serious rash has been observed among people taking armodafinil. Studies demonstrating these side effects required regular use of armodafinil; participation in our study only requires taking a single 250mg dose. Participants will be advised of these possible adverse reactions. Participants will remain at the clinic for testing for 4 hours following the drug administration and the principal investigator, Dr. Lynch, will be available to address any adverse event. The study will also require participants to complete tests of thinking and fill out questionnaires. Though there are typically no risks associated with these tasks, occasionally participants become frustrated when they feel they are doing poorly on a behavioral task or may feel uncomfortable when asked questions about their MS symptoms. Participants will be advised that they can discontinue the study at any time and that they can decline to answer any question. Inclusion/exclusion criteria: 40 participants with secondary progressive or relapsing-remitting MS will be included in the study. Interested participants will be administered a structured screening interview to determine their eligibility for the project by evaluating the following inclusion criteria: (a) no history of alcohol/drug abuse or nervous system disorder other than MS; (b) no sensory impairments that might interfere significantly with cognitive testing; (c) no developmental history of learning disability or attention-deficit/hyperactivity disorder; (d) no medical condition other than MS that could substantially affect cognition; (e) no relapse and/or corticosteroid use within four weeks of assessment; (f) absence of severe physical/neurological impairment that would make testing insurmountable; (g) and no current use of armodafinil or other psychostimulants; (h) not currently pregnant or breastfeeding; (i) no history of severe renal or hepatic impairment; (j) no history of heart disease. Because high doses of caffeine have been shown to have similar cognitive enhancing effects as armodafinil, only patients who report consuming fewer than 300mg caffeine daily will be included in the study. Each patient will be diagnosed as having MS based on established criteria by a board-certified neurologist who will determine disease duration, assess disease course based on Lublin & Reingold criteria, and rate patients on Kurtzke s EDSS. Additionally, interested participants will complete a brief cognitive screen at the time of the screening interview; the oral version of the Symbol Digit Modalities Test (SDMT) is a measure of speed of information processing that is commonly used in multiple sclerosis. Having shown 2
3 promise as a screening tool for cognitive impairment in MS, only patients who perform below established screening cutoffs on the SDMT will be accepted into the study. Study procedures: Participants will be approached during regularly scheduled meetings at the Landon Center MS clinic. If they express interest in learning more about the study and report a history of cognitive difficulties, they will be given informed consent. If they agree to participate following informed consent, an eligibility interview will be conducted. Additionally, female patients will be asked to provide a urine sample in order to test for potential pregnancy prior to both testing sessions. Moreover, patients will be told not to consume caffeine the day of testing or eat any food for three hours prior to the administration of the pill, in order to ensure a more standardized peak plasma concentration among all participants. Patients who report MS-related cognitive difficulties and perform at least one standard deviation below the mean on a brief cognitive screen will be given a thorough neuropsychological evaluation at two time points. The investigation will involve a double-blind, placebo controlled, cross-over study examining the efficacy of armodafinil in reducing cognitive problems in MS. Half of the patients will be randomized to receive a single oral dose of lactose placebo prior to the first testing session. After a weeklong washout period, they will then receive 250mg of armodafinil prior to a second testing session (P/M group). The other half of patients will be randomized to receive the active drug first, followed by the placebo (M/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions. Dr. Lynch will be prescribing and dispensing the armodafinil and placebo for this study. Cephalon will ship both the armodafinil and lactose placebo tablets to Dr. Bruce, who will securely transport them to Dr. Lynch upon their arrival. Dr. Lynch will place both the armodafinil and lactose placebo tablets in a locked cabinet upon her receipt of the tablets; the tablets will remain locked until dispensed by Dr. Lynch. Primary outcome measures for the study are computer and paper/pencil tests of attention, concentration, memory, and other types of thinking. In addition, we will be giving questionnaires that assess self-reported thinking skills, depression, fatigue, anxiety, and other common MS symptoms. Cognitive Measures Cognition will be examined with well-validated neuropsychological measures of intelligence, speed of information processing, attention, executive functioning, and learning. The most common cognitive problems in MS are speed of information processing and attention. As armodafinil has shown special promise in augmenting attention and speed of information processing, emphasis will be placed on neuropsychological tasks that measure these domains. In addition, we will administer a test of effort that has been shown to be highly correlated with self-reported cognitive fatigue in MS. When possible, counterbalanced alternate test forms will be given to minimize potential practice effects (please see Appendix A for a more detailed description of the proposed neuropsychological measures). 3
4 Self-Report Measures Patients will complete commonly used self-report questionnaires assessing current cognitive difficulties and medication-related side-effects. Cognitive fatigue will be measured using a standard measure of MS fatigue and a modified measure that asks participants to rate their fatigue at the moment of the evaluation. The modified measure will coincide with estimated peak plasma concentrations of armodafinil. As emotional problems have sometimes been linked to cognitive difficulties and fatigue in MS, questionnaires assessing mood and anxiety will also be administered. Safety Procedures Plan to monitor and report unanticipated problems: Unanticipated problems will be reported by research team members to Dr. Lynch who is responsible for project oversight. Dr. Lynch will notify other team members of the unanticipated problem and will convene a meeting with all team members to resolve the problem when necessary. Any adverse events will be reported to the Human Subjects Committee at The University of Kansas Hospital, as well as the Institutional Review Board at the University of Missouri-Kansas City, Cephalon and the FDA. A study timeline will be created which will include scheduling of quarterly meetings to monitor study procedures and data collection and entering. Plan to follow-up with participants: The research assistant will contact each participant by phone 24 hours following each testing session and inquire about how they are feeling, whether they have concerns about any part of the study in which they have participated. The research assistant will then coordinate with Dr. Lynch to address any follow-up issues if they arise. Plan to provide contact information to participants: Information regarding how to contact the investigators on the study will be provided to participants in the consent form, which they will have a signed copy of, in the event they should need to or desire to contact investigators for any reason. Study withdrawal/discontinuation procedures: The research assistant will inform the subject that he/she may terminate participation in the study at any time. The research assistant will observe the subject through the course of this testing. If the subject is unable to perform the tasks presented, becomes emotionally upset over his/her performance, becomes fatigued or confused by the testing, or in any other way, gives evidence of problems that would lead to sub-optimum performance, the research assistant will discontinue the testing and indicate the reason for this discontinuation in the record form. 4
5 Plan for assuring participants privacy and confidentiality: To ensure privacy and confidentiality, the consent process will take place in a private room in the Multiple Sclerosis clinic as part of usual clinic care. The study will be conducted in a private room at the neurology clinic. The name of the subject will be recorded on a single page record form, along with the subject number, age, gender, ethnicity, date of birth, education level, date of diagnosis, and EDSS disability score. Only principal and co-investigators will have access to the record form linking subject numbers with the subjects names. This file will be kept separate from all collected data in a locked file cabinet. The record forms are destroyed when all the data have been collected and the experiment is complete. All raw data will be kept separate from identifying information in a locked cabinet in which only the research team has access. A data spreadsheet will identify subjects by subject number, but not by name and will be stored in a password protected data file. Furthermore, the spreadsheet is shared only by individuals associated with the study and will be retained electronically for five years following publication of any results of this study, as required by sound research practices. However, following the completion of the experiment, there is no way of associating specific individuals with the data recorded in this spreadsheet. 5
6 Appendix Neuropsychological Tests I. Attention and Speed of Information Processing Conner s Continuous Performance Test II (Conners, 2004): The CPT-II is a test of sustained attention, impulsivity, and choice reaction time that has negligible practice effects. The CPT-II has been shown to be sensitive to treatment effects of nootropics in various patient populations. Symbol Digit Modalities Test (Smith, 1982): The oral version of the SDMT is a measure of speed of information processing that is commonly used in multiple sclerosis. Having shown promise as a screening tool for cognitive impairment in MS, only patients who perform below established screening cutoffs on the SDMT will be accepted into the study (Parmenter, et al., 2007). The SDMT will also be used as an outcome measure. Paced Serial Addition Task (Gronwall, 1977): Commonly used a measure of speed of information processing in MS, the PASAT requires participants to quickly add numbers. II. Executive Functioning Stroop Test (Stroop, 1935) A test of executive functioning that requires participants to inhibit a natural response (reading a word) and replace it with another response (saying a color). Word Generation (Stern & White, 2003) A test of a verbal fluency in which a person is asked to generate as many 3 letter words as possible from a random list of letters. Computerized Assessment of Response Bias (Allen et al., 1997): The CARB is a measure of effort and response time variability that has been shown to be highly correlated with selfreported fatigue in MS (Bruce et al., In Press). III. Memory Rey Auditory Verbal Learning Test (Lezak et al., 2004) A test of verbal memory during which a person is asked to learn and recall a list of 15 unrelated words. This test has multiple alternate forms that can be used to reduce practice effects. Brief Visuospatial Memory Test (Benedict et al., 1996) A test of visual memory during which a person is asked to learn and draw a series of abstract designs. This test has multiple alternate forms that can be used to reduce practice effects. IV. General Intellectual Functioning 6
7 Wechsler Test of Adult Reading (Wechsler, 2001): The WTAR will be used as an estimate of intellectual abilities. This test uses a mixture of demographic information and performance on a reading test to accurately estimate general intellectual functioning. Self-Report Measures BDI-Fast Screen (Beck et al., 2000) A self-report questionnaire designed to assess depression in neurologic populations. The Prospective and Retrospective Memory Questionnaire (Smith et al., 2000) A self-report questionnaire designed to assess perceived memory problems. Current Cognition Questionnaire Self-report measure designed to assess the cognitive problems a person is experiencing at the moment they are filling out the questionnaire. Modified Fatigue Impact Scale (Fisk et al., 1994) - A self-report measure designed to assess cognitive, physical, and social fatigue in MS. Current Fatigue Impact Scale Self-report measure designed to assess the fatigue a person is feeling at the moment they are filling out the questionnaire. Epworth Sleepiness Scale (Johns, 1991) A self-report measure designed to assess how tired a person is. State-Trait Anxiety Inventory (Spielberger, 1983) A self-report measure designed to assess situational and stable anxiety. References 7
8 Allen, L., Conder, R., Green, P., & Cox, D. (1997). CARB 97 : Computerized Assessment of Response Bias. Durham, NC : CogniSyst. Baranski, J., Cian, C., Esquivie, D., Pigeau, R., & Raphel, C. (1998). Modafinil during 64 hours of sleep deprivation: dose related effects on fatigue, alertness, and cognitive performance. Military Psychology, 10(3), Baranski, J., Pigeau, R., Dinich, P., Jacobs, I. (2004). Effects of modafinil on cognitive and meta-cognitive performance. Human Psychopharmacology: Clinical and Experimental, 19, Beck, A., Steer, R., Brown, G. (2000). BDI- Fastscreen for Medical Patients. The Psychological Corporation. Benedict, R., Schretlen, D., Groninger, L., Dobraski, M. (1996). Revision of the brief visuospatial memory test: studies of normal performance, reliability, and validity. Psychological Assessment, 8 (2), Brassington, J.C. & Marsh, N.V. (1998). Neuropsychological aspects of multiple sclerosis. Neuropsychology Review, 8, Bruce, J., Bruce, A., & Arnett, P. (In Press). Response variability is associated with selfreported cognitive fatigue in multiple sclerosis. Neuropsychology. Conners (2004). Conner s Continuous Performance Test (CPT-II). Multi-Health Systems, Inc., North Tonawanda, NY. Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994). The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21, Gill, M., Haerich, P., Westcott, K., Godenick, K., Tucker, J. (2006). Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double blind randomized crossover study. Academic Emergency Medicine, 13, Gronwall, D. Paced auditory serial addition task: a measure of recovery from concussion. Perception and Motor Skills, 44(2), Harsh, J., Hayduk, R., Rosenberg, R., Wesnes, K., Walsh, J., Arora, S., Niebler, G., & Roth T. (2006). The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Current Medical Research and Opinion, 22(4), Higginson, C.I., Arnett, P.A., & Voss, W.D. (2000). The ecological validity of clinical tests of memory and attention in multiple sclerosis. Archives of Clinical Neuropsychology, 15,
9 Hirshkowitz, M., Black, J., Wesness, K., Niebler, G., Arora, S., & Roth, T. (2007). Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respiratory Medicine, 101 (3), Johns (1991). A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep, 14 (6), Kurtzke, J. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33, Lezak, M., Howieson, D., Loring, D., Hannay, H., Fischer, J. (2004). Neuropsychological Assessment. New York, NY: Oxford University Press Lublin, F.D. & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46, McDonald, W., Compston, A., Goodkin, D., Hartung, H., Lublin, F et al. (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology, 50, Muller, U., Steffenhagen, N., & Regenthal, R. (2004). Effects of modafinil on working memory processes in humans. Psychopharmacology, 177, Parmenter, B., Guttman, B., Garg, N., Munschauer, F., & Benedict, R (2007). Screening for cognitive impairment in multiple sclerosis using the Symbold Digit Modalities Test. Multiple Sclerosis, 13, Polman, C., Reingold, S., Edan, G., Filippi, M., Hartung, H., Kappos, L et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions of the McDonald Criteria. Annals of Neurology, 58(6), Randall, D., Shneerson, J., & File, S. (2005a). Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacology, Biochemistry, and Behavior, 82, Randall, D., Viswanath, A., Bharania, P., Elsabagh, S., Hartley, D., Shneerson, J., File, S. (2005b). Does modafinil enhance cognitive performance in young volunteers who are not sleep deprived? Journal of Clinical Psychopharmacology, 25(2), Rao, S.M., Leo, G.J., Ellington, L., Nauertz, T., Bernardin, L., & Unverzagt, F. (1991). Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology, 39, Roth, T., White, D., Schmidt-Nowara, W., Wesnes, K., Niebler, G., Arora, S., & Black, J. (2006). Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in ncpap adherent adults. Clin Ther, 28 (5),
10 Roth, T., Rippon, G., & Arora, S. (2008). Armodafinil improves wakefulness and long-term episodic memory in ncpap adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath, 12(1), Stern, R & White, T. (2003). Neuropsychological Assessment Battery. Lutz, FL. Psychological Assessment Resources. Smith, G., Della Salla, S., Logi, R., Maylor, E. (2000). Prospective and retrospective memory in normal aging and dementia: a questionnaire study. Memory, 8(5), Smith, A. (1982). Symbol Digit Modalities Test. Western Psychological Services, Los Angeles. Speilberger, C. (1983). Manual for the State-Trait Anxiety Inventory (STAI). Palo Alto: Consulting Psychologists Press. Stroop, J. (1935). Studies of interference in serial verbal reactions. Journal of Experimental Psychology, 18, Turner, D., Clark, L., Dowson, J., Robbins, T., Sahakian, B. (2004a). Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biological Psychiatry, 55(10), Turner, D., Clark, L., Pomarol-Clotet, E., McKenna, P., Robbins, T., Sahakian, B. (2004b). Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology, 29, Wechsler (2001). Wechsler Test of Adult Reading. New York: The Psychological Corporation. Zifko, U. (2004). Management of fatigue in patients with multiple sclerosis. Drugs, 64(12),
Patricia Beldotti, Psy.D. Email: drbeldotti@aol.com Tel: 520-404-7553 Web: www.drbeldotti.com
Patricia Beldotti, Psy.D. Email: drbeldotti@aol.com Tel: 520-404-7553 Web: www.drbeldotti.com Assessment Costs I understand that assessment needs differ and that these assessments can be costly, especially
More informationNUVIGIL (armodafinil) oral tablet
NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationUniversity of St. Thomas Health Services and Counseling ADD/ADHD Guidelines
University of St. Thomas Health Services and Counseling ADD/ADHD Guidelines Students with suspected or diagnosed ADD/ADHD may present in different circumstances. These guidelines were developed to provide
More informationTHE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine
THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine Volume 1, Issue 1 August 2007 The Depression Research Clinic at Stanford University
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationPSYCHOLOGICAL AND NEUROPSYCHOLOGICAL TESTING
Status Active Medical and Behavioral Health Policy Section: Behavioral Health Policy Number: X-45 Effective Date: 01/22/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More information5.07.04. Provigil Nuvigil. Provigil (modafinil) / Nuvigil (armodafinil) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.04 Subject: Provigil Nuvigil Page: 1 of 6 Last Review Date: June 19, 2015 Provigil Nuvigil Description
More informationThe effects of caffeine on alertness: a randomized trial Morrocona MM, Smith A, Jones FH
RESEARCH The effects of caffeine on alertness: a randomized trial Morrocona MM, Smith A, Jones FH TRIAL DESIGN A randomized controlled trial was employed in which participants were randomly allocated to
More informationPsychological and Neuropsychological Testing
Psychological and Neuropsychological Testing I. Policy University Health Alliance (UHA) will reimburse for Psychological and Neuropsychological Testing (PT/NPT) when it is determined to be medically necessary
More informationSelf-reported Memory Problems in Multiple Sclerosis: Influence of Psychiatric Status and Normative Dissociative Experiences
Archives of Clinical Neuropsychology Advance Access published December 3, 2009 Self-reported Memory Problems in Multiple Sclerosis: Influence of Psychiatric Status and Normative Dissociative Experiences
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of
More informationDocumentation Requirements ADHD
Documentation Requirements ADHD Attention Deficit Hyperactivity Disorder (ADHD) is considered a neurobiological disability that interferes with a person s ability to sustain attention, focus on a task
More informationTESTING GUIDELINES PerformCare: HealthChoices. Guidelines for Psychological Testing
TESTING GUIDELINES PerformCare: HealthChoices Guidelines for Psychological Testing Testing of personality characteristics, symptom levels, intellectual level or functional capacity is sometimes medically
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationDisability Services Office Health, Counselling & Disability Services
Queen s University Documentation Requirements for Students with Learning Disabilities The following outlines the specific type and format of documentation that students with learning disabilities (LD)
More informationGuidelines for Documentation of a A. Learning Disability
Guidelines for Documentation of a Learning Disability A. Learning Disability B. Attention Deficit Disorder C. Psychiatric Disabilities D. Chronic Health Disabilities A. Learning Disability Students who
More informationIntegrated Visual and Auditory (IVA) Continuous Performance Test
DISCLAIMER The information contained within this document does not constitute medical advice or diagnosis and is intended for education and information purposes only. It was current at the time of publication
More informationClinician Portal: Enabling a Continuity of Concussion Care
Clinician Portal: Enabling a Continuity of Concussion Care www.concussionvitalsigns.com Clinician Portal: Enabling a Continuity of Concussion CARE The Clinician Portal advances sports concussion care by
More informationGuidelines for Documentation of a Learning Disability (LD) in Gallaudet University Students
Guidelines for Documentation of a Learning Disability (LD) in Gallaudet University Students Gallaudet University Office for Students with Disabilities Washington, D.C. 20002 2 Guidelines for Documentation
More informationNew perception of disability including cognition, fatigue, pain and other impairments related to MS
New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for
More informationMedical Information to Support the Decisions of TUECs INTRINSIC SLEEP DISORDERS
Introduction Excessive daytime sleepiness (EDS) is a common complaint. Causes of EDS are numerous and include: o Intrinsic sleep disorders (e.g. narcolepsy, obstructive sleep apnoea/hypopnea syndrome (OSAHS)
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationSPECIFICATIONS FOR PSYCHIATRIC AND PSYCHOLOGICAL EVALUATIONS
SPECIFICATIONS FOR PSYCHIATRIC AND PSYCHOLOGICAL EVALUATIONS Why are both a psychiatric and a psychological evaluation required? Mental disorders, as well as the medications used for treatment, may produce
More informationDEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
More informationGuidelines for the Documentation of a Learning Disability in Adolescents and Adults
C O N C O R D I A C O L L E G E M O O R H E A D M I N N E S O TA COUNSELING CENTER, 901 8 TH STREET SOUTH, MOORHEAD, MN 56562 Guidelines for the Documentation of a Learning Disability in Adolescents and
More informationMELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES
MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES Version control: Version Date Main changes/comments V1 4 June 2013 First draft circulated
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fampridine Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationMellen Center Approaches: Identifying and managing cognitive disorders in MS
Mellen Center Approaches: Identifying and managing cognitive disorders in MS Framework: Cognitive dysfunction is common in the MS population. It affects quality of life and correlates with worsened disease
More informationDocumentation Guidelines for ADD/ADHD
Documentation Guidelines for ADD/ADHD Hope College Academic Success Center This document was developed following the best practice recommendations for disability documentation as outlined by the Association
More informationAccommodations STUDENTS WITH DISABILTITES SERVICES
Accommodations Otis College of Art and Design is committed to providing equality of education opportunity to all students. To assist in increasing the student s learning outcome, Students with Disabilities
More informationStudy Protocol Template
Study Protocol Template (Chart Reviews) Instructions: This protocol template is a tool to facilitate the development of a study protocol specifically designed for the investigator initiated studies. It
More informationThe Relationship Between Anhedonia & Low Mood
Rebecca M. Floyd, Ph.D., Kimberly Lewis, Ph.D., Eliot Lopez, M.S., Thomas Toomey, B.A., Kena Arnold, B.A., and Lara Stepleman, Ph.D. The lifetime prevalence of depression in patients with MS is approximately
More informationEfficacy and safety of modafinil (Provigil ) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study
179 PAPER Efficacy and safety of modafinil (Provigil ) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study K W Rammohan, J H Rosenberg, D J Lynn, A M Blumenfeld, C P Pollak,
More informationRelapsing-remitting multiple sclerosis Ambulatory with or without aid
AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date
More informationUniversity of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
More informationBOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 bps@aphanet.org www.bpsweb.
BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 bps@aphanet.org www.bpsweb.org Content Outline for the PSYCHIATRIC PHARMACY SPECIALTY
More informationThe Role of Neuropsychology in the Treatment of MS
The Role of Neuropsychology in the Treatment of MS Jeffrey Wilken, Ph.D. Director of Research Neuropsychology Associates of Fairfax Assistant Professor of Neurology Georgetown University Medical Center
More informationClinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1
Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease
More informationSLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS
E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep
More informationClinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder
Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder AACAP Official Action: OUTLINE OF PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN, ADOLESCENTS, AND ADULTS WITH ADHD
More information#3: SAMPLE CONSENT FORM
#3: SAMPLE CONSENT FORM [Key Element #3: Who is conducting the study] UPMC University of Pittsburgh Medical Center Western Psychiatric Institute and Clinic CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH
More informationWritten Example for Research Question: How is caffeine consumption associated with memory?
Guide to Writing Your Primary Research Paper Your Research Report should be divided into sections with these headings: Abstract, Introduction, Methods, Results, Discussion, and References. Introduction:
More informationPsychological and Neuropsychological Testing
2015 Level of Care Guidelines Psych & Neuropsych Testing Psychological and Neuropsychological Testing Introduction: The Psychological and Neuropsychological Testing Guidelines provide objective and evidencebased
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationCompleting your Personal Health Application New York Applicants
Completing your Personal Health Application New York Applicants Purpose These instructions will help you to complete your Personal Health Application. This will help ensure that your application is processed
More informationTrileptal (Oxcarbazepine)
Brand and Generic Names: Trileptal Tablets: 150mg, 300mg, 600mg Liquid Suspension: 300mg/5mL Generic name: oxcarbazepine What is Trileptal and what does it treat? Trileptal (Oxcarbazepine) Oxcarbazepine
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationHow To Know If You Can Remember To Remember Recipe Cards
Pharmacology, Biochemistry and Behavior 82 (2005) 133 139 www.elsevier.com/locate/pharmbiochembeh Cognitive effects of modafinil in student volunteers may depend on IQ Delia C. Randall a,b, John M. Shneerson
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationProfessional Certificate in Primary Care Psychology
Professional Certificate in Primary Care Psychology The NAPPP Primary Care Psychology Certificate training program requires the completion of 10 courses. Each course awards 15 CE credit hours. NAPPP is
More informationSECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage
SECTION 2 Multiple Sclerosis (MS) Drug Coverage Section 2 Multiple Sclerosis (MS) Drug Coverage ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Selected Drug Products used in the treatment of patients with
More informationProgress in MS: Current and Emerging Therapies
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the
More informationRECOMMENDED QUANTITY LIMITS 1,2. Table 1: Summary of Recommended Doses and Quantity Limits
Nuvigil TM / Provigil Prior Authorization Criteria Brand Generic Dosage Form Nuvigil TM armodafinil tablet Provigil modafinil tablet FDA APPROVED INDICATIONS 1,2 The following information is taken from
More informationIntravenous Methyl Prednisolone in Multiple Sclerosis
Intravenous Methyl Prednisolone in Multiple Sclerosis Exceptional healthcare, personally delivered Relapse management in multiple sclerosis Relapses in multiple sclerosis (MS) are common and caused by
More informationIBADAN STUDY OF AGEING (ISA): RATIONALE AND METHODS. Oye Gureje Professor of Psychiatry University of Ibadan Nigeria
IBADAN STUDY OF AGEING (ISA): RATIONALE AND METHODS Oye Gureje Professor of Psychiatry University of Ibadan Nigeria Introduction The Ibadan Study of Ageing consists of two components: Baseline cross sectional
More informationEarly Response Concussion Recovery
Early Response Concussion Recovery KRISTA MAILEY, BSW RSW, CONCUSSION RECOVERY CONSULTANT CAREY MINTZ, PH.D., C. PSYCH., PRACTICE IN CLINICAL NEUROPSYCHOLOGY FOR REFERRAL: Contact Krista Mailey at (204)
More informationCOURSE APPROVAL GUIDELINES APS COLLEGE OF CLINICAL NEUROPSYCHOLOGISTS
Page 1 COURSE APPROVAL GUIDELINES APS COLLEGE OF CLINICAL NEUROPSYCHOLOGISTS Updated October 2000 Page 2 1. General Introduction and Principles Clinical neuropsychology is a division of psychology concerned
More informationBehavioral Health Psychological/Neuropsychological Testing Guidelines
Behavioral Health Psychological/Neuropsychological Testing Guidelines Psychological testing (procedural code 96101) and Neuropsychological Testing (procedural code 96118) involve the culturally and linguistically
More informationIF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)
IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationMeeting the Needs of Aging Persons. Aging in Individuals with a
Meeting the Needs of Aging Persons with Developmental Disabilities Cross Network Collaboration for Florida Aging in Individuals with a Developmental Disability Module 3 Based on ADRC training developed
More informationACUTE EFFECTS OF LORATADINE, DIPHENHYDRAMINE AND PLACEBO, ALONE AND WITH ALCOHOL, ON SKILLS PERFORMANCE
ACUTE EFFECTS OF LORATADINE, DIPHENHYDRAMINE AND PLACEBO, ALONE AND WITH ALCOHOL, ON SKILLS PERFORMANCE C. Jeavons Wilkinson and Herbert Moskowitz University of California at Los Angeles (UCLA) and Southern
More informationExpectancy Effects of Performance Enhancing Supplements on Motivation to Exercise. Chris Dawson and Alfonso Ribero.
Running Head: EXPECTANCY EFFECTS ON MOTIVATION Expectancy Effects of Performance Enhancing Supplements on Motivation to Exercise Chris Dawson and Alfonso Ribero Hanover College Expectancy Effects 2 Abstract
More informationDEPRESSION CODING FACT SHEET FOR PRIMARY CARE CLINICIANS
DEPRESSION CODING FACT SHEET FOR PRIMARY CARE CLINICIANS Current Procedural Terminology (CPT ) (Procedure) Codes Initial assessment usually involves a lot of time determining the differential diagnosis,
More informationFact Sheet 10 DSM-5 and Autism Spectrum Disorder
Fact Sheet 10 DSM-5 and Autism Spectrum Disorder A diagnosis of autism is made on the basis of observed behaviour. There are no blood tests, no single defining symptom and no physical characteristics that
More informationEastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families
Eastern Health MS Service Tysabri Therapy Information for People with MS and their Families The Eastern Health MS Service has developed this information for you as a guide through what will happen to you
More information1695 N.W. 9th Avenue, Suite 3302H Miami, FL. 33136. Days and Hours: Monday Friday 8:30a.m. 6:00p.m. (305) 355 9028 (JMH, Downtown)
UNIVERSITY OF MIAMI, LEONARD M. MILLER SCHOOL OF MEDICINE CLINICAL NEUROPSYCHOLOGY UHEALTH PSYCHIATRY AT MENTAL HEALTH HOSPITAL CENTER 1695 N.W. 9th Avenue, Suite 3302H Miami, FL. 33136 Days and Hours:
More informationIs the experience and expression of living with severe MS ethnically and culturally patterned?
WHO Collaborating Centre for Palliative Care, Policy and Rehabilitation Is the experience and expression of living with severe MS ethnically and culturally patterned? Dr Jonathan Koffman Cicely Saunders
More informationMENTAL IMPAIRMENT RATING
MENTAL IMPAIRMENT RATING Lev.II Curriculum Rev. 6/09 155 OBJECTIVES MENTAL AND BEHAVIORAL DISORDERS 1. Identify the axes used in the diagnostic and statistical manual of mental disorders - DSM. 2. Understand
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) FOCUSED QUESTION Does a neurocognitive habilitation therapy service improve executive functioning and emotional and social problem-solving skills in children with fetal
More informationUnderstanding Relapse in Multiple Sclerosis. A guide for people with MS and their families
Understanding Relapse in Multiple Sclerosis A guide for people with MS and their families Introduction You have been given this booklet because you have been diagnosed with Multiple Sclerosis (MS) and
More informationGuidelines for the Clinical Research Program Test Accommodations Request Process
Guidelines for the Clinical Research Program Test Accommodations Request Process Introduction The Clinical Research Program (CRP) provides reasonable and appropriate accommodations in accordance with the
More informationIntegrated Neuropsychological Assessment
Integrated Neuropsychological Assessment Dr. Diana Velikonja C.Psych Neuropsychology, Hamilton Health Sciences, ABI Program Assistant Professor, Psychiatry and Behavioural Neurosciences Faculty of Health
More informationThe Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
More informationPostpartum Depression and Post-Traumatic Stress Disorder
Postpartum Depression and Post-Traumatic Stress Disorder Emotional Recovery: Postpartum Depression and Post-Traumatic Stress Disorder By: Lisa Houchins Published: July 23, 2013 Emotions vary widely after
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More informationComorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Gold R, Giovannoni G, Selmaj K, et al, for
More informationElectroconvulsive Therapy - ECT
Electroconvulsive Therapy - ECT Introduction Electroconvulsive therapy, or ECT, is a safe and effective treatment that may reduce symptoms related to depression or mental illness. During ECT, certain parts
More informationMental Disorders (Except initial PTSD and Eating Disorders) Examination
Mental Disorders (Except initial PTSD and Eating Disorders) Examination Name: Date of Exam: SSN: C-number: Place of Exam: The following health care providers can perform initial examinations for Mental
More informationVITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS
39 Chapter 3 VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS Maxine Briggs TABLE OF CONTENTS I. Review of the
More informationFAA EXPERIENCE WITH NEUROPSYCHOLOGICAL TESTING FOR AIRMEN WITH DEPRESSION ON SSRI MEDICATIONS
FAA EXPERIENCE WITH NEUROPSYCHOLOGICAL TESTING FOR AIRMEN WITH DEPRESSION ON SSRI MEDICATIONS Presented to: 2013 Aerospace Medical Association Annual Scientific Meeting By: James R. DeVoll, M.D. Date:
More informationOral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
More informationCognitive Rehabilitation for Executive Dysfunction in Parkinson s Disease
Calleo, J., Burrows, C., Levin, H., Marsh, L., Lai, E., York, M. (2012). Cognitive rehabilitation for executive dysfunction in Parkinson s disease: application and current directions., vol. 2012, Article
More informationNEUROPSYCHOLOGY QUESTIONNAIRE. (Please fill this out prior to your appointment and bring it with you.) Name: Date of appointment: Home address:
NEUROPSYCHOLOGY QUESTIONNAIRE (Please fill this out prior to your appointment and bring it with you.) Name: Date of appointment: Date of birth: Age: _ Home address: _ Home phone: Cell phone: Work phone:
More informationMedical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
More informationThe University of Memphis Guidelines for Documentation of a Learning Disability in Adolescents and Adults
The University of Memphis Guidelines for Documentation of a Learning Disability in Adolescents and Adults Introduction The prevailing legal climate surrounding higher education and disability issues, combined
More informationNEW TRENDS AND ISSUES IN NEUROPSYCHOLOGY: Mild Traumatic Brain Injury and Postconcussive Syndrome Cases
NEW TRENDS AND ISSUES IN NEUROPSYCHOLOGY: Mild Traumatic Brain Injury and Postconcussive Syndrome Cases Carl F. Mariano Barry H. Uhrman Introduction to Neuropsychology As many of you are aware, clinical
More informationMaster of Arts in Psychology: Counseling Psychology
Deanship of Graduate Studies King Saud University Master of Arts in Psychology: Counseling Psychology Department of Psychology College of Education Master of Arts in Psychology: Counseling Psychology 2007/2008
More informationMellen Center for Multiple Sclerosis
Mellen Center Cleveland Clinic Marie Namey, RN, MSN, MSCN Mellen Center Cleveland Clinic Cleveland, OH Home of. Mellen Center for Multiple Sclerosis Mellen Center Mission The Mellen Center remains committed
More informationSteps to getting a diagnosis: Finding out if it s Alzheimer s Disease.
Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease. Memory loss and changes in mood and behavior are some signs that you or a family member may have Alzheimer s disease. If you have
More informationChestnut Hill College Psychological Services Clinic. Informed Consent to Perform a Psychological Evaluation
Chestnut Hill College Psychological Services Clinic Informed Consent to Perform a Psychological Evaluation Welcome to Chestnut Hill s Psychological Services Clinic. This form will provide information about
More informationWhich injectable medication should I take for relapsing-remitting multiple sclerosis?
Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have
More informationAdult Information Form Page 1
Adult Information Form Page 1 Client Name: Age: DOB: Date: Address: City: State: Zip: Home Phone: ( ) OK to leave message? Yes No Work Phone: ( ) OK to leave message? Yes No Current Employer (or school
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationSativex. Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353
Sativex Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Sativex Date of issue: July 2010 Review date: July 2011 Contents 1. Introduction 1 2. What is Sativex?
More informationFrequently Asked Questions
Frequently Asked Questions Business Office: 598 Airport Boulevard Suite 1400 Morrisville NC 27560 Contact: support@cognitrax.com Phone: 888.750.6941 Fax: 888.650.6795 www.cognitrax.com Diseases of the
More informationADULT INTAKE QUESTIONNAIRE. Today s Date: Home phone: Ok to leave message? Yes No. Work phone: Ok to leave message? Yes No
ADULT INTAKE QUESTIONNAIRE Name: Today s Date: Age: Date of Birth: Address: Home phone: Ok to leave message? Yes No Work phone: Ok to leave message? Yes No Cell phone: Ok to leave message? Yes No Email:
More information